High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the doublestandard dose in an assay-dependent manner

Julie H. Oestreich; Steven R. Steinhubl; Suellen P. Ferraris; Wendell S. Akers

doi:10.1160/TH10-09-0603

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2011; 105(05): 927-930
DOI: 10.1160/TH10-09-0603

Letters to the Editor

Schattauer GmbH

High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the doublestandard dose in an assay-dependent manner

Julie H. Oestreich

¹University of Nebraska Medical Center Department of Pharmacy Practice, Omaha, Nebraska, USA

,

Steven R. Steinhubl

²Geisinger Health System, Danville, Pennsylvania, USA

,

Suellen P. Ferraris

³University of Kentucky Department of Surgery, Lexington, Kentucky, USA

,

Wendell S. Akers

⁴Lipscomb University Department of Pharmaceutical Sciences, Nashville, Tennessee, USA

References
1 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
2 Steinhubl SR, Berger PB, Mann JT. 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
3 Chen ZM, Jiang LX, Chen YP. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
4 Oestreich JH, Holt J, Dunn SP. et al. Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis 2009; 20: 207-213.
5 Aleil B, Jacquemin L, De Poli F. et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008; 1: 631-638.
6 Angiolillo DJ, Bernardo E, Palazuelos J. et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost 2008; 99: 161-168.
7 Palmerini T, Barozzi C, Tomasi L. et al. A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150mg/day versus 75mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study. Thromb Res 2010; 125: 309-314.
8 von Beckerath N, Kastrati A, Wieczorek A. et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814-1819.
9 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
10 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
11 Mehta SR, Tanguay JF, Eikelboom JW. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
12 GRAVITAS: No benefit of doubling dose in clopidogrel nonresponders. November 16, 2010. Available at http://www.theheart.org/article/1150629.do. Accessed January 4, 2011.
13 Akers WS, Oh JJ, Oestreich JH. et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010; 50: 27-35.
14 Steinhubl SR, Oh JJ, Oestreich JH. et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534.
15 Sibbing D, Steinhubl S, Schulz S. et al. Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients: Initial Evidence of a Therapeutic Window. J Am Coll Cardiol 2010; 56: 317-318.
16 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
17 Bal Dit Sollier C, Berge N, Boval B. et al. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 2009; 101: 116-122.
18 Hobson A, Curzen N. Improving outcomes with anti-platelet therapies in percutaneous coronary intervention and stenting. Thromb Haemost 2009; 101: 23-30.
19 Oestreich JH, Smyth SS, Campbell CL. Platelet function analysis: at the edge of meaning. Thromb Haemost 2009; 101: 217-219.
20 Gremmel T, Steiner S, Seidinger D. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
21 Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009; 102: 7-14.
22 Siller-Matula JM, Gouya G, Wolzt M. et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 102: 397-403.
23 Elsenberg EH, van Werkum JW, van de Wal RM. et al. The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
24 Hayward CP. Advances in understanding “high on-treatment platelet reactivity“. Thromb Haemost 2009; 102: 799-800.
25 Derhaschnig U, Jilma B. Assessment of platelets and the endothelium in patients presenting with acute coronary syndromes--is there a future?. Thromb Haemost 2009; 102: 1144-1148.
26 Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. Thromb Haemost 2010; 103: 29-33.
27 Bouman HJ, van Werkum JW, Rudez G. et al. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. Thromb Haemost 2010; 103: 379-386.
28 Zurn CS, Geisler T, Gawaz M. ADP-receptor blockade: A case for personalised pharmacotherapy?. Thromb Haemost 2010; 103: 496-506.
29 Sofi F, Marcucci R, Gori AM. et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848.
30 Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010; 103: 1128-1135.
31 Judge HM, Buckland RJ, Sugidachi A. et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
32 Marcucci R, Gori AM, Paniccia R. et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104: 279-286.
33 Paniccia R, Antonucci E, Maggini N. et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104: 287-292.
34 Bal Dit Sollier C, Berge N, Boval B. et al. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 2010; 104: 571-581.